Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: software salesperson who wrote (14973)	12/27/2004 5:12:43 PM
From: Biomaven	Respond to of 52153

aleve: i don't believe the results. Certainly possible, and based on previously published studies more than likely in my view. But you certainly can't conclude anything from your naprosyn sales figures - most of this usage isn't chronic, day-in-day-out by elderly folks at risk of cardiac events. And even if it was, the effect you are looking for could easily be swamped by other changes in the general population, like increased used of statins, better control of hypertension, reduced smoking, more exercise, etc. You are talking about a pretty small effect with lots of countervailing factors - the only way to nail it down is with a large randomized study. Peter